2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Cell Expansion, Clinical Procedures, Emerging Technologies, Treatment Considerations, Combination Therapy, Therapy Sequence, Biological Therapies, Transplantation, (CAR)-T Cell Therapies, Infusion, Adverse Events, Clinical Practice (Health Services and Quality), Quality Improvement, Value, Diseases, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Plasma Cell Disorders, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, ALL, B Cell Lymphoma, Research, Translational Research, Clinical Research, Study Population, Human, Adult, Elderly
PAPER

2418 Bioorthogonally engineered RNA-loaded lipid nanoparticles for in situ reprogramming of CAR-macrophages with synergistic CD47–SIRPα axis blockade in extranodal lymphoma therapy

Zhaozhao Chen, Hekuan Huang2, Xue Zhang, MS3, Anqi Ren, MS4, Yingying Li, MS5, Heng Mei, MD, PhD6
1 Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
2 Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
3 Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
4 Hubei Clinical Medical Center of Cell Therapy for Neoplastic Disease, Wuhan, China
5 Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
6 Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
Background:  Chimeric antigen receptor (CAR) T-cell therapy has revolutionized hematologic malignancy treatment, yet extranodal (EN) involvement, affecting up to 40% of non-Hodgkin lymphoma patients, remains a significant clinical challenge. EN lesions are characterized by a hostile tumor microenvironment (TME) rich in immunosuppressive M2-polarized tumor-associated macrophages (TAMs), which constitute > 50% of immune infiltrates and promote tumor progression, angiogenesis, and immune evasion. The CD47-SIRPα “do not eat me” axis further suppresses macrophage-mediated phagocytosis and antitumor immunity, contributing to CAR-T resistance. While CD47 blockade can reverse this signal, systemic anti-CD47 antibodies are limited by on-target off-tumor toxicity (anemia, thrombocytopenia) due to CD47 expression on erythrocytes and platelets. Current ex vivo CAR-macrophage (CAR-MΦ) manufacturing faces challenges including poor proliferation, limited in vivo persistence, and hepatic sequestration. Thus, innovative strategies for in situ generation of CAR-MΦ with safe and effective CD47-SIRPα pathway modulation are urgently needed.

Aims: We developed a bioorthogonally engineered mRNA-LNP platform for in situ reprogramming of M2Φ into CAR-M1Φ with concurrent SIRPα silencing, aiming to: (1) achieve dual-targeting TME via bioorthogonal click chemistry and actively binding; (2) co-deliver CD19 CAR and SIRPα siRNA (siSIRPα) for CAR-MΦ reprogramming and blocking the CD47-SIRPα axis selectively on macrophages, avoiding systemic anti-CD47 toxicity; and (4) evaluate antitumor efficacy and TME remodeling in EN lymphoma models.                     

Methods: We engineered mRNA-LNPs co-encapsulating CD19 CAR mRNAand SIRPα siRNA via microfluidic technology. LNPs were surface-modified with DBCO-PEG-lipid for bioorthogonal conjugation and Mannose (Man) for M2Φ targeting. Azide-modified nanoparticles (AZ-NPs) encapsulating Ac4ManNAZ were synthesized for metabolic labeling of TME. In vitro, M2Φ were generated from immortalized and primary macrophages. CAR expression, SIRPα knockdown efficiency, and M1 polarization were assessed by flow cytometry and ELISA. Phagocytosis and cytotoxicity against CD19+ tumor cells were evaluated by confocal microscopy and LDH release assays. 3D tumor spheroid models assessed CAR-MΦ penetration. In vivo efficacy was evaluated in humanized huHSC-NOG-EXL and PDX mouse models of EN lymphoma, with tumor growth monitored by bioluminescence imaging and TME remodeling analyzed by flow cytometry and immunohistochemistry.   

Results:  Bioorthogonal targeting significantly enhanced mRNA-LNP binding and transfection in M2Φ in vitro. Co-delivery of CAR mRNA and siSIRPα achieved robust CAR expression, efficient SIRPα knockdown, and marked M1 polarization with elevated pro-inflammatory cytokines (TNF-α, IL-12) and reduced IL-10 secretion. CAR-MΦ exhibited potent antigen-specific phagocytosis and cytotoxicity against CD19+ tumor cells, with SIRPα silencing further enhancing phagocytic activity compared to CAR alone. In 3D tumor spheroids, CAR-MΦ demonstrated superior penetration and tumor cell elimination. In vivo, bioorthogonal targeting achieved selective mRNA-LNP accumulation in EN tumor lesions. In situ reprogrammed CAR-MΦ significantly inhibited tumor growth, prolonged survival, and remodeled the TME by increasing the M1/M2 ratio, promoting CD8+ T-cell infiltration, and enhancing dendritic cell maturation. Importantly, no hematologic toxicity was observed, confirming the safety of macrophage-specific SIRPα silencing.

Conclusions:  This study establishes a bioorthogonally engineered mRNA-LNP platform for in situ CAR-MΦ reprogramming with concurrent SIRPα silencing, offering a novel “off-the-shelf” strategy to overcome CAR-T resistance in EN lymphoma. This approach achieves TME-specific targeting, efficient CAR expression, M1 polarization, and selective CD47-SIRPα pathway blockade without systemic toxicity, representing a promising translational platform for treating extranodal hematologic malignancies.
Zhaozhao Chen: No relevant conflicts of interest to declare.